Hikma Pharmaceuticals Invests in Mumbai-based Unimark Remedies; Hikma Will Pay $33 Million
in-Pharma -- MENA-focused drug manufacturer, Hikma, has entered into a strategic partnership with Indian API and intermediates business, Unimark Remedies. Under the agreement, Hikma will pay $33m (€23m) for a minority interest in the Mumbai-based API (active pharmaceutical ingredient) and intermediates manufacturer, whose range includes betalactams, cephalosporins and carbapenems.